Mesenchymal stem cell-derived migratory bodies, methods and uses thereof in treating vascular dementia combined with metabolic syndrome

The treatment of vascular dementia with metabolic syndrome using mesenchymal stem cell-derived migration bodies (HUC-MSC-MI) solves the problem that existing technologies fail to address both central nervous system damage and peripheral metabolic and immune disorders, achieving precise intervention and improvement of multiple organ functions in vascular dementia with metabolic syndrome.

CN122104572APending Publication Date: 2026-05-29TIANJIN HUANHU HOSPITAL (TIANJIN NEUROSURGICAL INSTITUTE TIANJIN NEUROLOGICAL DISEASE CENTER HOSPITAL)
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
TIANJIN HUANHU HOSPITAL (TIANJIN NEUROSURGICAL INSTITUTE TIANJIN NEUROLOGICAL DISEASE CENTER HOSPITAL)
Filing Date
2026-03-03
Publication Date
2026-05-29

AI Technical Summary

Technical Problem

Current strategies for treating vascular dementia mainly focus on the central nervous system, failing to systematically consider peripheral organ dysfunction and immune dysfunction associated with metabolic syndrome, resulting in limited treatment efficacy, especially in cases of vascular dementia combined with metabolic syndrome, where precise intervention strategies are lacking.

Method used

Using mesenchymal stem cell-derived migrasomes (HUC-MSC-MI), membrane-encapsulated vesicle structures formed during cell migration were extracted and identified by differential centrifugation. The migrasome-related proteins NDST1, C3orf64, and PGCP were expressed to treat vascular dementia complicated with metabolic syndrome and improve multiple organ dysfunction.

Benefits of technology

Migratory bodies can significantly improve cognitive impairment, cerebrovascular lesions, and metabolic and immune imbalances in patients with vascular dementia complicated by metabolic syndrome, and synergistically improve the pathological state of organs such as the brain, liver, intestines, and thymus, providing a novel treatment strategy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122104572A_ABST
    Figure CN122104572A_ABST
Patent Text Reader

Abstract

The application belongs to the technical field of biological medicine and regenerative medicine, and discloses a mesenchymal stem cell-derived migratory body, a method and application of the migratory body in treating vascular dementia combined with metabolic syndrome. The migratory body can detect migratory body-related proteins NDST1, C3orf64 and PGCP. A vesicle-like structure formed in the cell migration process can be observed, and the vesicle is connected with an elongated migration fiber, showing typical morphological characteristics of a migration-related vesicle. The vesicle-like structure is wrapped by a membrane, which is consistent with the ultrastructure characteristics of the migratory body formed and released in the cell migration process. The application first proposes and establishes a technical scheme of using the mesenchymal stem cell-derived migratory body to treat vascular dementia combined with metabolic syndrome. For the complex disease involving central nervous injury and systemic metabolism and immune disorder, the application provides a new intervention strategy and technical path.
Need to check novelty before this filing date? Find Prior Art